ProstaLund AB (PLUN) - Total Assets
Based on the latest financial reports, ProstaLund AB (PLUN) holds total assets worth Skr55.84 Million SEK (≈ $6.01 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of ProstaLund AB for net asset value and shareholders' equity analysis.
ProstaLund AB - Total Assets Trend (2012–2024)
This chart illustrates how ProstaLund AB's total assets have evolved over time, based on quarterly financial data.
ProstaLund AB - Asset Composition Analysis
Current Asset Composition (December 2024)
ProstaLund AB's total assets of Skr55.84 Million consist of 42.9% current assets and 57.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 12.7% |
| Accounts Receivable | Skr4.28 Million | 6.9% |
| Inventory | Skr14.35 Million | 23.3% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr34.38 Million | 55.8% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how ProstaLund AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of ProstaLund AB.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProstaLund AB's current assets represent 42.9% of total assets in 2024, a decrease from 56.9% in 2012.
- Cash Position: Cash and equivalents constituted 12.7% of total assets in 2024, up from 10.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 24.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 55.8% of total assets.
ProstaLund AB Competitors by Total Assets
Key competitors of ProstaLund AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ramsay Health Care Ltd
AU:RHC
|
Australia | AU$22.48 Billion |
|
Top Choice Medical Investment Co Inc
SHG:600763
|
China | CN¥6.28 Billion |
|
InnovAge Holding Corp
NASDAQ:INNV
|
USA | $510.23 Million |
|
P3 Health Partners Inc
NASDAQ:PIII
|
USA | $683.56 Million |
|
Vibhavadi Medical Center Public Company Limited
BK:VIBHA
|
Thailand | ฿24.30 Billion |
|
Mahachai Hospital Public Company Limited
BK:M-CHAI
|
Thailand | ฿11.27 Billion |
|
PACS Group, Inc.
NYSE:PACS
|
USA | $5.63 Billion |
|
Acadia Healthcare Company Inc
NASDAQ:ACHC
|
USA | $6.41 Billion |
ProstaLund AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 2.06 | 5.03 |
| Quick Ratio | 0.59 | 0.76 | 3.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr8.62 Million | Skr12.49 Million | Skr17.16 Million |
ProstaLund AB - Advanced Valuation Insights
This section examines the relationship between ProstaLund AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.07 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -5.9% |
| Total Assets | Skr61.64 Million |
| Market Capitalization | $716.78K USD |
Valuation Analysis
Below Book Valuation: The market values ProstaLund AB's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ProstaLund AB's assets decreased by 5.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ProstaLund AB (2012–2024)
The table below shows the annual total assets of ProstaLund AB from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr61.64 Million ≈ $6.63 Million |
-5.91% |
| 2023-12-31 | Skr65.51 Million ≈ $7.05 Million |
+28.34% |
| 2022-12-31 | Skr51.04 Million ≈ $5.49 Million |
+17.39% |
| 2021-12-31 | Skr43.48 Million ≈ $4.68 Million |
+41.00% |
| 2020-12-31 | Skr30.84 Million ≈ $3.32 Million |
+16.86% |
| 2019-12-31 | Skr26.39 Million ≈ $2.84 Million |
+37.76% |
| 2018-12-31 | Skr19.16 Million ≈ $2.06 Million |
+6.87% |
| 2017-12-31 | Skr17.92 Million ≈ $1.93 Million |
-49.13% |
| 2016-12-31 | Skr35.23 Million ≈ $3.79 Million |
+30.00% |
| 2015-12-31 | Skr27.10 Million ≈ $2.92 Million |
+70.93% |
| 2014-12-31 | Skr15.86 Million ≈ $1.71 Million |
+64.98% |
| 2013-12-31 | Skr9.61 Million ≈ $1.03 Million |
+39.01% |
| 2012-12-31 | Skr6.91 Million ≈ $744.06K |
-- |
About ProstaLund AB
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow, a temporary prostate stent; Oruflow, a urine flow meter; and Schelin Catheter, a medical device intended for intraprostatic and periprostatic injection of legally mark… Read more